| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2012-09-13 11:47:09 UTC |
|---|
| Update Date | 2021-09-14 15:45:32 UTC |
|---|
| HMDB ID | HMDB0041905 |
|---|
| Secondary Accession Numbers | - HMDB0060598
- HMDB0060972
- HMDB41905
- HMDB60598
- HMDB60972
|
|---|
| Metabolite Identification |
|---|
| Common Name | 4-Hydroxyphenytoin |
|---|
| Description | 4-Hydroxyphenytoin, also known as 4'-HPPH, belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. In humans, 4-hydroxyphenytoin is involved in the metabolic disorder called the phenytoin (antiarrhythmic) action pathway. 4-Hydroxyphenytoin is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on 4-Hydroxyphenytoin. |
|---|
| Structure | OC1=NC(C(O)=N1)(C1=CC=CC=C1)C1=CC=C(O)C=C1 InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20) |
|---|
| Synonyms | | Value | Source |
|---|
| (Hydroxyphenyl)phenylhydantoin | ChEBI | | (p-Hydroxyphenyl)phenylhydantoin | ChEBI | | 4-Hydroxydiphenylhydantoin | ChEBI | | 5-(4'-Hydroxyphenyl)-5-phenylhydantoin | ChEBI | | 5-(p-Hydroxyphenyl)-5-phenylhydantoin | ChEBI | | Hydroxydiphenylhydantoin | ChEBI | | Hydroxyphenytoin | ChEBI | | p-Hydroxydiphenylhydantoin | ChEBI | | p-Hydroxyphenytoin | ChEBI | | Para-hydroxyphenytoin | ChEBI | | 5-(4-Hydroxyphenyl)-5-phenyl-2,4-imidazolidinedione | HMDB | | 5-(4-Hydroxyphenyl)-5-phenylhydantoin | HMDB | | 5-(p-Hydroxyphenyl)-5-phenyl-hydantoin | HMDB | | Hydroxyphenytoin, (R)-isomer | HMDB | | 4'-HPPH | HMDB | | 4-HPPH | HMDB | | Hydroxyphenytoin, (+-)-isomer | HMDB | | Hydroxyphenytoin, (S)-isomer | HMDB | | Hydroxyphenytoin, 11C-labeled | HMDB |
|
|---|
| Chemical Formula | C15H12N2O3 |
|---|
| Average Molecular Weight | 268.2674 |
|---|
| Monoisotopic Molecular Weight | 268.08479226 |
|---|
| IUPAC Name | 4-(4-hydroxyphenyl)-4-phenyl-4H-imidazole-2,5-diol |
|---|
| Traditional Name | 5-(4-hydroxyphenyl)-5-phenylimidazole-2,4-diol |
|---|
| CAS Registry Number | 2784-27-2 |
|---|
| SMILES | OC1=NC(C(O)=N1)(C1=CC=CC=C1)C1=CC=C(O)C=C1 |
|---|
| InChI Identifier | InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20) |
|---|
| InChI Key | XEEDURHPFVXALT-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Azolidines |
|---|
| Sub Class | Imidazolidines |
|---|
| Direct Parent | Phenylhydantoins |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- 5-phenylhydantoin
- Phenylimidazolidine
- Alpha-amino acid or derivatives
- 5-monosubstituted hydantoin
- 1-hydroxy-2-unsubstituted benzenoid
- N-acyl urea
- Phenol
- Ureide
- Monocyclic benzene moiety
- Benzenoid
- Dicarboximide
- Urea
- Carbonic acid derivative
- Carboxylic acid derivative
- Azacycle
- Carbonyl group
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 1.70 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.41 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.7521 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.21 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 28.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 4-Hydroxyphenytoin,1TMS,isomer #1 | C[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O)=N1 | 2498.1 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,1TMS,isomer #2 | C[Si](C)(C)OC1=NC(O)=NC1(C1=CC=CC=C1)C1=CC=C(O)C=C1 | 2492.7 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,1TMS,isomer #3 | C[Si](C)(C)OC1=CC=C(C2(C3=CC=CC=C3)N=C(O)N=C2O)C=C1 | 2558.6 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TMS,isomer #1 | C[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O[Si](C)(C)C)C=C2)C(O)=N1 | 2505.3 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TMS,isomer #2 | C[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O[Si](C)(C)C)=N1 | 2448.5 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TMS,isomer #3 | C[Si](C)(C)OC1=NC(O)=NC1(C1=CC=CC=C1)C1=CC=C(O[Si](C)(C)C)C=C1 | 2502.8 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,3TMS,isomer #1 | C[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O[Si](C)(C)C)C=C2)C(O[Si](C)(C)C)=N1 | 2540.9 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O)=N1 | 2722.2 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=NC(O)=NC1(C1=CC=CC=C1)C1=CC=C(O)C=C1 | 2717.9 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=C(C2(C3=CC=CC=C3)N=C(O)N=C2O)C=C1 | 2795.1 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C(O)=N1 | 2926.0 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O)C=C2)C(O[Si](C)(C)C(C)(C)C)=N1 | 2851.6 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=NC(O)=NC1(C1=CC=CC=C1)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1 | 2922.8 | Semi standard non polar | 33892256 | | 4-Hydroxyphenytoin,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=NC(C2=CC=CC=C2)(C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C(O[Si](C)(C)C(C)(C)C)=N1 | 3072.4 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Jurgens U: Routine determination of hydroxyphenytoin in urine by high-performance liquid chromatography using an automatic column-switching technique. J Chromatogr. 1983 Jul 8;275(2):335-43. [PubMed:6619238 ]
- Sato A, Shimada K, Izumo Y, Sakaguchi T: High-performance liquid chromatographic determination of phenytoin and hydroxyphenytoin in human urine. J Chromatogr. 1983 Jun 10;275(1):97-105. [PubMed:6874875 ]
- Zeng J, Liu D, Zou Y: [High performance liquid chromatographic determination of hydroxyphenytoin in human urine]. Hua Xi Yi Ke Da Xue Xue Bao. 1992 Sep;23(3):321-4. [PubMed:1298726 ]
- Shimada K, Wakabayashi H, Sato A: Gas chromatographic determination of m- and p-hydroxyphenytoin in the urine of epileptic patients. J Chromatogr. 1985 May 3;339(2):331-7. [PubMed:4008572 ]
- Chou RC, Levy G: Effect of pregnancy on the pharmacokinetics of phenytoin in rats. J Pharmacol Exp Ther. 1984 May;229(2):351-8. [PubMed:6716263 ]
- Rambeck B, May T: Urinary hydroxyphenytoin/creatinine ratios as an index of compliance in adult epileptic patients on phenytoin therapy. Ther Drug Monit. 1984;6(2):164-72. [PubMed:6740735 ]
- Horsmans Y, Van den Berge V, Bouckaert A, Desager JP: Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion. Pharmacol Toxicol. 1997 Dec;81(6):276-9. [PubMed:9444669 ]
- Yamanaka H, Nakajima M, Hara Y, Katoh M, Tachibana O, Yamashita J, Yokoi T: Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. Drug Metab Pharmacokinet. 2005 Apr;20(2):135-43. [PubMed:15855726 ]
|
|---|